Plant Name: Atractylodes lancea
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADORA3; ADORA2A; ADORA1; FFAR1; FFAR4; | |
| GLA; FAAH; RECQL; ADK; TERT; GLO1; NOX4; ALOX12; AKR1B1; HSD17B10; HPGD; ALOX15; PARP1; TNKS; TNKS2; POLB; CD38; | |
| ACHE; | |
| TRPA1; | |
| GSK3B; FLT3; | |
| CA2; CA1; CA12; CA9; CA3; CA14; CA7; CA4; | |
| PPARA; PPARD; PPARG; | |
| ALOX5; MAOA; PTGS1; XDH; | |
| KDM4E; | |
| MMP9; MMP12; MMP2; | |
| CASP1; CASP7; | |
| TLR2; | |
| HIF1A; TP53; STAT6; | |
| ABCG2; | |
| SLC28A2; SLC28A3; SLC28A1; | |
| XPO1; HTT; LMNA; FABP3; FABP5; FABP2; FABP4; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | XPO1 | Exportin-1 | O14980 | CHEMBL5661 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.539E-12 | 7.705E-09 | CA1, CA12, CA14, CA2, CA3, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.132E-11 | 4.909E-08 | CA1, CA12, CA2, CA3, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.231E-09 | 1.675E-06 | CA1, CA12, CA2, CA3, CA4, CA7, CA9, GLO1, MMP12, MMP2, MMP9, PARP1, PPARA, PPARD, PPARG, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.271E-07 | 3.326E-05 | ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.210E-07 | 5.406E-05 | ABCG2, ACHE, ADORA2A, APP, CASP1, CD38, FLT3, GLA, HPGD, HTT, MMP9, PARP1, PPARG, SMN1, SMN2, STAT6, TERT, TP53, TRPA1, TTR, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.950E-07 | 6.691E-05 | ALOX12, ALOX15, ALOX5, HPGD |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.021E-07 | 8.844E-05 | ADORA1, ADORA2A, AKR1B1, ALOX12, CD38, FFAR4, GLO1, GSK3B, HIF1A, HTT, LMNA, MMP9, PPARD, TERT, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.337E-07 | 1.341E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 9.566E-07 | 1.965E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.166E-06 | 2.351E-04 | HPGD, MMP2, MMP9, TERT |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.199E-06 | 2.396E-04 | ADORA1, ADORA2A, CA2, CA7, CD38, HIF1A, HTT, PARP1, TNKS, TNKS2, TRPA1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.408E-06 | 2.736E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.648E-06 | 3.041E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.000E-06 | 3.569E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 3.935E-06 | 6.209E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0040011; locomotion | GO:0030334; regulation of cell migration | 4.205E-06 | 6.502E-04 | ADORA1, ADORA3, ALOX12, APP, CYP1B1, HIF1A, LMNA, MMP9, NOX4, PPARD, PPARG, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.892E-06 | 7.397E-04 | ALOX12, ALOX15, ALOX5, TLR2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.606E-06 | 8.304E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 7.577E-06 | 1.046E-03 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS1 |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 1.083E-05 | 1.404E-03 | ADORA1, AKR1B1, ALOX15, APP, CASP1, CYP1B1, FFAR4, FLT3, HTT, NOX4, PPARD, TLR2, TP53, XDH |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.126E-05 | 1.442E-03 | ADORA1, ADORA2A, CA2, CA7, HTT, PARP1, TRPA1 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.326E-05 | 1.603E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 1.332E-05 | 1.603E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.332E-05 | 1.603E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.332E-05 | 1.603E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.332E-05 | 1.603E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 1.332E-05 | 1.603E-03 | SLC28A2, SLC28A3 |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 1.487E-05 | 1.759E-03 | ADORA1, CD38, PARP1, TNKS, TNKS2, TRPA1 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 1.540E-05 | 1.813E-03 | ACHE, ADORA1, ADORA2A, AKR1B1, ALOX15, APP, CA2, CYP1A1, CYP1A2, CYP1B1, FABP5, FLT3, GSK3B, HIF1A, HPGD, HTT, LMNA, MMP9, POLB, PPARA, PPARD, PPARG, SMN1, SMN2, TLR2, TP53, TSHR |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.926E-05 | 2.231E-03 | ADORA2A, CA2, CA7, HIF1A, HTT, TNKS, TNKS2 |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 2.098E-05 | 2.379E-03 | TERT, TNKS, TNKS2 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 3.030E-05 | 3.332E-03 | ADORA1, ADORA2A, PPARA, PPARG, TP53 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.119E-05 | 3.395E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 3.672E-05 | 3.885E-03 | CYP1B1, GLA, HIF1A, NOX4, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 3.733E-05 | 3.889E-03 | ADORA2A, PPARG, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 3.987E-05 | 3.964E-03 | APP, TLR2 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 3.987E-05 | 3.964E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.987E-05 | 3.964E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 3.987E-05 | 3.964E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.987E-05 | 3.964E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.987E-05 | 3.964E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.987E-05 | 3.964E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.987E-05 | 3.964E-03 | ADORA1, ADORA2A |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 4.033E-05 | 3.992E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 4.613E-05 | 4.425E-03 | NOX4, PARP1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 4.613E-05 | 4.425E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 4.833E-05 | 4.596E-03 | AKR1B1, CYP1A1, CYP1B1, CYP3A4, TTR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 4.833E-05 | 4.596E-03 | AKR1B1, CYP1B1, MMP9, STAT6, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 4.908E-05 | 4.646E-03 | AKR1B1, CA9, CD38, PARP1, PPARG, TLR2 |
| BP | GO:0065007; biological regulation | GO:0050790; regulation of catalytic activity | 5.262E-05 | 4.939E-03 | ADORA1, ADORA2A, ADORA3, APP, CASP1, CASP7, FABP4, FLT3, GLA, GSK3B, HIF1A, HTT, MMP9, NOX4, PARP1, PPARG, TERT, TNKS, TP53, TSHR, XDH |
| BP | GO:0008152; metabolic process | GO:0031328; positive regulation of cellular biosynthetic process | 5.772E-05 | 5.348E-03 | ADORA2A, APP, CD38, FABP3, HIF1A, MMP12, NOX4, PARP1, PPARA, PPARD, PPARG, STAT6, TERT, TLR2, TNKS, TNKS2, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.036E-05 | 5.522E-03 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 6.266E-05 | 5.662E-03 | ADORA1, CA2, CA4, CA9, HPGD, TSHR |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 6.970E-05 | 6.170E-03 | HIF1A, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 7.955E-05 | 6.714E-03 | TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 7.955E-05 | 6.714E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.955E-05 | 6.714E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.955E-05 | 6.714E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.995E-05 | 6.721E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 9.113E-05 | 7.516E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.033E-04 | 8.329E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.078E-04 | 8.634E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 1.143E-04 | 9.081E-03 | CD38, FFAR1, HIF1A, PPARD |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.153E-04 | 9.130E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, HIF1A, HTT, TP53, TRPA1 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 1.164E-04 | 9.133E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.307E-04 | 9.845E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.307E-04 | 9.845E-03 | APP, GSK3B, PARP1 |
| BP | GO:0008152; metabolic process | GO:0045935; positive regulation of nucleobase-containing compound metabolic process | 1.312E-04 | 9.845E-03 | ADORA2A, APP, CD38, HIF1A, MMP12, NOX4, PARP1, PPARA, PPARD, PPARG, STAT6, TERT, TLR2, TNKS, TNKS2, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.323E-04 | 9.845E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.323E-04 | 9.845E-03 | PPARA, PPARG |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.279E-04 | 9.845E-03 | GSK3B, HIF1A, HTT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.323E-04 | 9.845E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.398E-16 | 1.522E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.978E-16 | 6.125E-14 | CA12; CA1; CA3; CA2; CA4; CA7; CA9; CA14 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 4.753E-09 | 3.660E-07 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.871E-06 | 1.474E-04 | APP; MAOA; ALOX5; ALOX15; ALOX12; PTGS1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.210E-05 | 4.658E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 8.021E-05 | 1.544E-03 | GSK3B; FLT3; MMP2; PPARG; HIF1A; TP53; MMP9; PPARD |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.658E-05 | 1.374E-03 | FABP4; ADORA1; TSHR; PTGS1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.963E-05 | 1.532E-03 | ALOX5; ALOX15; ALOX12; PTGS1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.352E-05 | 1.374E-03 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.319E-04 | 2.031E-03 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.726E-04 | 4.414E-03 | MAOA; ALOX15; ADK; AKR1B1; ALOX12; CYP3A4; HSD17B10; PTGS1; ALOX5; CYP1A2; CYP1A1; CD38; XDH |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.069E-04 | 2.656E-03 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.757E-04 | 7.027E-03 | MMP2; TP53; HIF1A; MMP9; TLR2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.499E-04 | 4.619E-03 | HPGD; FLT3; PPARG; TP53; MMP9 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.149E-04 | 4.563E-03 | MMP2; MMP9; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.554E-03 | 1.232E-02 | CASP7; PARP1; LMNA; TP53 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.455E-04 | 7.027E-03 | ALOX5; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.466E-04 | 2.053E-03 | CYP1A2; ALOX15; CYP3A4 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.812E-03 | 1.269E-02 | STAT6; TP53; MMP9; TLR2 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 9.853E-04 | 8.430E-03 | CASP7; CASP1; TLR2 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.237E-03 | 1.378E-02 | POLB; GSK3B; XPO1; TERT; TP53 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.745E-03 | 1.269E-02 | FLT3; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.599E-03 | 1.232E-02 | CYP1A2; CYP1A1; CYP3A4 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.014E-03 | 1.719E-02 | APP; GSK3B; CASP7; HSD17B10 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.899E-03 | 1.272E-02 | MAOA; CYP1A2; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.497E-03 | 2.822E-02 | ADORA2A; ADORA1; PPARA; TSHR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 5.792E-03 | 2.878E-02 | GSK3B; XPO1; CD38; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.061E-03 | 1.323E-02 | CA2; CYP3A4; ABCG2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.551E-03 | 3.990E-02 | GSK3B; TP53; HIF1A |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 8.952E-03 | 4.055E-02 | ADORA3; ADORA1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.742E-03 | 2.608E-02 | PPARG; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.069E-03 | 2.692E-02 | AKR1B1; GLA |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 6.110E-03 | 2.941E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.996E-03 | 1.719E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.234E-04 | 2.031E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH; MAOA; ACHE |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; MMP2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; ADORA2A; MMP12; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ADORA2A; ADORA1; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; ALOX5; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; ADORA1; FFAR1; AKR1B1; PPARG |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR; APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9; MMP9; TLR2; MMP2; XPO1 |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; MAOA; ACHE; ACHE; ACHE; APP; PPARG; PPARG |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; PTGS1; MMP12; FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; PPARG |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1; CA1; CA1; AKR1B1; ACHE |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| NA: NA | Edema | NA | CA2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; ADORA2A; ADK; FAAH; TRPA1; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; TLR2 |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; MAOA; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; ADK; MAOA |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; PTGS1; MMP2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; PARP1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; CD38 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1; MAOA; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2; TERT; MMP2 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; ADORA2A; ADORA1; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD; MMP12 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | GSK3B; ADORA3; HIF1A; TP53; CA1; FLT3; FLT3; CA9; MMP9; TLR2; PARP1; MMP2; XPO1; ACHE; APP; CD38 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; ADORA1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; TP53; FLT3; MMP9 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; PARP1; MMP2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TLR2; TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |